HIM
IBIO icon

Hillsdale Investment Management’s iBio IBIO Stock Holding History

Hillsdale Investment Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32
Closed -$61 – 707
2026
Q1 		$61 Buy
+32
New +$74 ﹤0.01% 653

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Hillsdale Investment Management's IBIO Position: Q2 2026 in Review

Hillsdale Investment Management sold out of iBio (IBIO) in Q2 2026, closing a stake of 32 shares — an estimated $61 sold.

Hillsdale Investment Management first reported a position in IBIO in Q1 2026 and held it in 1 quarter. The position peaked at $61 in Q1 2026. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Hillsdale Investment Management reported no remaining iBio position as of Q2 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 32 iBio shares in Q2 2026, an estimated $61.
  • Hillsdale Investment Management first reported a position in iBio in Q1 2026 and held it in 1 quarter.
  • Hillsdale Investment Management's iBio position peaked at $61 in Q1 2026.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.